Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors.,Journal of Clinical Oncology

当前位置： X-MOL 学术 › J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2024-05-29 , DOI: 10.1200/jco.2024.42.16_suppl.e15010
Jim Coward ₁ , Ganessan Kichenadasse ₂ , John J. Park ₃ , Sagun Parakh ₄ , Gary Edward Richardson ₅ , Mark Voskoboynik ₆ , John D. Powderly ₇ , Zhengbo Song ₈ , Shutong Liu ₉ , Yaling Huang ₁₀ , Shu-Hui Liu ₉ , Xun Meng ₁₀

Affiliation